Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
|
Aug 2020
|
Journal of Patient-Reported Outcomes
|
myelodysplastic syndromes (MDS)
|
Ocular complications in a young pediatric population following bone marrow transplantation
|
Jan 2018
|
Journal of the American Academy of Pediatric Oncology and Strabsimus
|
aplastic anemia
|
Progress in the Management of Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Review
|
Jan 2024
|
Journal of Women's Health
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
A Primary Care Approach to Myelodysplastic Syndromes
|
May 2014
|
Korean J Fam Med
|
myelodysplastic syndromes (MDS)
|
Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes?
|
Jun 2023
|
Lancet
|
myelodysplastic syndromes (MDS)
|
Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes?
|
Jul 2023
|
Lancet
|
myelodysplastic syndromes (MDS)
|
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
|
Jun 2023
|
Lancet
|
myelodysplastic syndromes (MDS)
|
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
|
Jan 2024
|
Lancet
|
myelodysplastic syndromes (MDS)
|
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
|
Jul 2023
|
Lancet
|
myelodysplastic syndromes (MDS)
|
Myelodysplastic syndromes
|
Mar 2014
|
Lancet
|
myelodysplastic syndromes (MDS)
|